[go: up one dir, main page]

PL2922875T3 - Przeciwciała anty-CEACAM5 i ich zastosowanie - Google Patents

Przeciwciała anty-CEACAM5 i ich zastosowanie

Info

Publication number
PL2922875T3
PL2922875T3 PL13794894T PL13794894T PL2922875T3 PL 2922875 T3 PL2922875 T3 PL 2922875T3 PL 13794894 T PL13794894 T PL 13794894T PL 13794894 T PL13794894 T PL 13794894T PL 2922875 T3 PL2922875 T3 PL 2922875T3
Authority
PL
Poland
Prior art keywords
ceacam5 antibodies
ceacam5
antibodies
Prior art date
Application number
PL13794894T
Other languages
English (en)
Inventor
Pierre-Francois Berne
Francis Blanche
Hervé Bouchard
Béatrice Cameron
Tarik Dabdoubi
Stéphanie Decary
Paul Ferrari
Alexey Rak
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of PL2922875T3 publication Critical patent/PL2922875T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13794894T 2012-11-20 2013-11-20 Przeciwciała anty-CEACAM5 i ich zastosowanie PL2922875T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306444 2012-11-20
EP13794894.9A EP2922875B1 (en) 2012-11-20 2013-11-20 Anti-ceacam5 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
PL2922875T3 true PL2922875T3 (pl) 2017-08-31

Family

ID=47257727

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13794894T PL2922875T3 (pl) 2012-11-20 2013-11-20 Przeciwciała anty-CEACAM5 i ich zastosowanie
PL17157890T PL3199552T3 (pl) 2012-11-20 2013-11-20 Przeciwciała anty-CEACAM5 i ich zastosowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17157890T PL3199552T3 (pl) 2012-11-20 2013-11-20 Przeciwciała anty-CEACAM5 i ich zastosowania

Country Status (38)

Country Link
US (4) US9617345B2 (pl)
EP (3) EP2922875B1 (pl)
JP (1) JP6324399B2 (pl)
KR (4) KR102194748B1 (pl)
CN (2) CN109180815B (pl)
AR (1) AR093557A1 (pl)
AU (2) AU2013349733C1 (pl)
BR (1) BR112015010993B1 (pl)
CA (2) CA2889962C (pl)
CL (1) CL2015001321A1 (pl)
CR (1) CR20150258A (pl)
CY (1) CY1119219T1 (pl)
DK (2) DK3199552T3 (pl)
DO (1) DOP2015000110A (pl)
EA (1) EA039377B1 (pl)
EC (1) ECSP15025845A (pl)
ES (2) ES2778823T3 (pl)
HR (2) HRP20170743T1 (pl)
HU (1) HUE033369T2 (pl)
IL (1) IL238559B (pl)
LT (2) LT3199552T (pl)
MA (1) MA38194B1 (pl)
MX (1) MX358321B (pl)
MY (1) MY171100A (pl)
NZ (1) NZ708528A (pl)
PE (1) PE20151180A1 (pl)
PH (1) PH12015501092B1 (pl)
PL (2) PL2922875T3 (pl)
PT (2) PT3199552T (pl)
RS (2) RS55987B1 (pl)
SG (1) SG11201503285TA (pl)
SI (2) SI2922875T1 (pl)
TN (1) TN2015000177A1 (pl)
TW (2) TW201940519A (pl)
UA (1) UA120247C2 (pl)
UY (1) UY35147A (pl)
WO (1) WO2014079886A1 (pl)
ZA (1) ZA201502959B (pl)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015010993B1 (pt) 2012-11-20 2022-08-30 Sanofi Anticorpos anti-ceacam5, célula hospedeira, imunoconjugado e composição farmacêutica
US9753036B2 (en) * 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
EP3311846A1 (en) * 2014-09-02 2018-04-25 ImmunoGen, Inc. Methods for formulating antibody drug conjugate compositions
BR112018000835A2 (pt) 2015-10-02 2018-09-11 Hoffmann La Roche molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
WO2017118675A1 (en) 2016-01-08 2017-07-13 F. Hoffmann-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
AU2017343377B2 (en) * 2016-10-10 2024-07-11 Agency For Science, Technology And Research Anti-CEACAM6 antibodies and methods of use
EP3543337B1 (en) 2016-11-18 2022-04-20 Astellas Pharma Inc. Novel anti-human muc1 antibody fab fragment
CN111499750B (zh) * 2016-12-04 2022-02-08 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的高中和活性纳米抗体及其应用
CN108341876B (zh) * 2017-01-22 2021-06-04 中国人民解放军第四军医大学 抗人ceacam5单克隆抗体及其制备方法和应用
CN106946989B (zh) * 2017-03-02 2020-02-18 深圳市国创纳米抗体技术有限公司 抗cea抗原vhh结构域及含有其的双特异性抗体
TWI795415B (zh) * 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
KR20200027551A (ko) * 2017-07-11 2020-03-12 화이자 인코포레이티드 Cea muc1 및 tert를 포함하는 면역원성 조성물
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
CN112020519A (zh) 2018-03-13 2020-12-01 酵活有限公司 抗her2双互补位抗体-药物偶联物及使用方法
US11505610B2 (en) 2018-04-06 2022-11-22 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
EP3781592A4 (en) * 2018-04-20 2023-01-11 The Regents of the University of California Treatment of prostate cancer using chimeric antigen receptors
EP3795590A4 (en) 2018-05-17 2022-05-04 Astellas Pharma Inc. COMPLEX HAVING ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT, PEPTIDE LINKER AND/OR LIGAND
KR20210029158A (ko) 2018-06-03 2021-03-15 람카프 바이오 베타 엘티디. Ceacam5 및 cd47에 대한 이중특이성 항체
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
CN110684107B (zh) * 2018-07-06 2021-03-23 中国人民解放军第四军医大学 抗MG7-Ag的单克隆抗体(MGd1)及其用途
CN110684108B (zh) * 2018-07-06 2021-06-04 中国人民解放军第四军医大学 抗MG7-Ag的单克隆抗体(CEA37)及其用途
CN113365663A (zh) 2018-08-30 2021-09-07 Hcw生物科技公司 单链嵌合多肽和其用途
EP3844182B1 (en) 2018-08-30 2025-05-14 ImmunityBio, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
AU2019328290B2 (en) 2018-08-30 2024-10-10 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof
MY205764A (en) * 2018-10-10 2024-11-12 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
CN111487411B (zh) * 2019-01-29 2023-05-09 瑞博奥(广州)生物科技股份有限公司 Ceacam1多肽的新应用
US20220080053A1 (en) 2019-02-07 2022-03-17 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
EP3693023A1 (en) 2019-02-11 2020-08-12 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
US20220218607A1 (en) * 2019-04-23 2022-07-14 Sanofi Stable, low-viscosity antibody formulations and uses thereof
KR20220016943A (ko) * 2019-06-04 2022-02-10 바이오세우스 인크. 항 씨이에이씨에이엠5 단클론 항체 및 그의 제조 방법 및 그의 용도
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
TW202112752A (zh) 2019-06-13 2021-04-01 美商博特生物治療公司 胺基苯并氮呯化合物、免疫接合物及其用途
AU2020294797A1 (en) 2019-06-21 2021-12-23 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof
JP7354306B2 (ja) 2019-06-27 2023-10-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
CA3148694A1 (en) 2019-09-03 2021-03-11 Romas Kudirka Aminoquinoline compounds, immunoconjugates, and uses thereof
CA3150265A1 (en) 2019-09-18 2021-03-25 Sara MAJOCCHI BISPECIFIC ANTIBODIES DIRECTED AGAINST CEACAM5 AND CD3
CA3152601A1 (en) 2019-09-30 2021-04-08 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
BR112022007719A2 (pt) 2019-10-25 2022-07-12 Bolt Biotherapeutics Inc Imunoconjugados, composto ligante, composição farmacêutica, método para tratar câncer, uso de um imunoconjugado e método de preparação de um imunoconjugado
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
JP2023519106A (ja) 2020-02-11 2023-05-10 エイチシーダブリュー バイオロジックス インコーポレイテッド クロマトグラフィー樹脂およびその使用
WO2021163369A2 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
JP2023519107A (ja) 2020-02-11 2023-05-10 エイチシーダブリュー バイオロジックス インコーポレイテッド 制御性ｔ細胞を活性化する方法
KR20230005203A (ko) * 2020-04-24 2023-01-09 사노피 항-ceacam5 항체 접합체 및 folfox를 함유하는 항종양 조합
MX2022013404A (es) 2020-04-24 2022-11-14 Sanofi Sa Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5, trifluridina y tipirazilo.
MX2022013406A (es) * 2020-04-24 2022-11-14 Sanofi Sa Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y cetuximab.
EP4138924A1 (en) * 2020-04-24 2023-03-01 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
US20230293716A1 (en) 2020-05-08 2023-09-21 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
KR20230031280A (ko) 2020-06-01 2023-03-07 에이치씨더블유 바이올로직스, 인크. 노화 관련 장애의 치료 방법
CN111690061B (zh) * 2020-06-28 2022-08-23 中国人民解放军东部战区疾病预防控制中心 人源化抗鼠疫耶尔森菌抗原f1的抗体及应用
CN113105548B (zh) * 2020-08-04 2022-03-29 中山大学附属第五医院 抗ceacam5纳米抗体
KR20230051189A (ko) 2020-08-13 2023-04-17 볼트 바이오테라퓨틱스 인코퍼레이티드 피라졸로아제핀 면역접합체, 및 그의 용도
CN116724052A (zh) 2020-08-20 2023-09-08 A2生物治疗股份有限公司 用于治疗ceacam阳性癌症的组合物和方法
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
IL302731A (en) * 2020-11-10 2023-07-01 Sanofi Sa Ceacam5 antibody-drug conjugate formulation
WO2022116079A1 (zh) * 2020-12-03 2022-06-09 上海吉倍生物技术有限公司 一种抗ceacam5的人源化抗体及其制备方法和用途
EP4259210A2 (en) 2020-12-11 2023-10-18 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
CA3202255A1 (en) 2020-12-21 2022-06-30 Hayley WARSINSKE Markers for the early detection of colon cell proliferative disorders
CN112521509B (zh) * 2020-12-23 2022-07-08 姚雪英 一种抗ceacam5人源化抗体、其缀合物及其用途
AU2022233150A1 (en) * 2021-03-08 2023-09-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education MOLECULES THAT BIND TO CD66e POLYPEPTIDES
WO2022204536A1 (en) 2021-03-26 2022-09-29 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
CN117940168A (zh) 2021-03-26 2024-04-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
WO2022242681A1 (en) * 2021-05-21 2022-11-24 Beigene, Ltd. Anti-cea antibodies and methods of use
WO2023057564A1 (en) 2021-10-07 2023-04-13 Sanofi IMIDAZO[4,5-c]QUINOLINE-4-AMINE COMPOUNDS AND CONJUGATES THEREOF, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATIONS
JP2024542095A (ja) 2021-11-05 2024-11-13 サノフイ 抗ｃｅａｃａｍ５抗体－薬物コンジュゲート及び抗ｖｅｇｆｒ－２抗体を含む抗腫瘍組合せ
KR20240112922A (ko) 2021-12-02 2024-07-19 사노피 Ceacam5 adc - 항-pd1/pd-l1 병용 요법
JP2024545428A (ja) 2021-12-02 2024-12-06 サノフイ 癌治療における患者選択のためのｃｅａアッセイ
US20250188170A1 (en) * 2022-02-25 2025-06-12 Atyr Pharma, Inc. COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2b ANTIBODIES
CN119095611A (zh) 2022-03-02 2024-12-06 免疫生物有限公司 治疗胰腺癌的方法
TW202346354A (zh) * 2022-03-09 2023-12-01 德商馬克專利公司 抗ceacam5抗體及其結合物及用途
AU2023237620A1 (en) 2022-03-23 2024-08-29 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
PE20250928A1 (es) 2022-08-10 2025-04-02 Merck Sharp And Dohme Llc Proteinas de union a nkg2d, cd16 y ceacam5
WO2024140905A1 (en) * 2022-12-28 2024-07-04 Full-Life Technologies Hk Limited Antibodies specifically binding to ceacam5
TW202502387A (zh) 2023-03-01 2025-01-16 法商賽諾菲公司 抗ceacam5免疫接合物用於治療表現ceacam5的神經內分泌癌症之用途
EP4427763A1 (en) 2023-03-06 2024-09-11 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
CN117545780A (zh) * 2023-05-16 2024-02-09 成都优洛生物科技有限公司 抗lilrb1纳米抗体或其抗原结合片段、制备方法和用途
WO2024250924A1 (en) * 2023-06-05 2024-12-12 Nona Biosciences (Suzhou) Co., Ltd. Anti-ceacam5/6 dual-binding antibodies
TW202513094A (zh) 2023-06-05 2025-04-01 法商賽諾菲公司 含有抗ceacam5抗體藥物接合物、抗pd1/pd-l1抗體及抗ctla4抗體之抗腫瘤組合
WO2025031923A1 (en) 2023-08-04 2025-02-13 Sanofi Imidazo[4,5-d]pyridazine compounds and conjugates thereof, their preparation, and their therapeutic applications
CN119978136A (zh) * 2023-11-10 2025-05-13 信达生物制药(苏州)有限公司 抗dr5和ceacam5的双特异性抗体及其用途
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4791A (en) 1846-10-03 john g
US5204A (en) 1847-07-24 james cantelo
US689A (en) 1838-04-13 Julius austin
US144A (en) 1837-03-11 Improvement in scythe-snaths
US417A (en) 1837-09-28 Endless-ghain horse-power for driving iviaci-iii
US4670A (en) 1846-07-28 Improvement in fish-hooks
US4301A (en) 1845-12-11 Ebenezbr barrows
US835A (en) 1838-07-12 X i i i x
US4496A (en) 1846-05-02 Machinery for
US4640A (en) 1846-07-14 Book-lock
US192A (en) 1837-05-15 Machine for cutting
US244A (en) 1837-06-30 Edward flint
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
WO1994019478A1 (en) 1993-02-22 1994-09-01 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
US5994524A (en) 1994-07-13 1999-11-30 Chugai Seiyaku Kabushiki Kaisha Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
DE69633973T2 (de) 1995-09-11 2005-12-22 Kyowa Hakko Kogyo Co., Ltd. Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CA2287084A1 (en) 1997-04-10 1998-10-15 Royal Netherlands Academy Of Arts And Sciences Diagnosis method and reagents
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
WO2004016801A2 (en) 2002-08-16 2004-02-26 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
JP2006526408A (ja) 2003-04-22 2006-11-24 アイビーシー、ファーマシューティカルズ 多価タンパク質複合体
RS55181B1 (sr) 2005-12-21 2017-01-31 Amgen Res (Munich) Gmbh Farmaceutske kompozicije sa rezistencijom na rastvorljivi cea
KR101528939B1 (ko) 2006-07-18 2015-06-15 사노피 암 치료를 위한 ｅｐｈａ2에 대한 길항제 항체
KR101486615B1 (ko) * 2007-07-16 2015-01-28 제넨테크, 인크. 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
UY31309A1 (es) 2007-08-29 2009-03-31 Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CN102076717B (zh) 2008-04-30 2016-02-03 伊缪诺金公司 交联剂和它们的用途
CN102482701B (zh) * 2009-09-16 2015-05-13 免疫医疗公司 I类抗-cea抗体及其使用
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
HRP20180147T1 (hr) * 2011-03-02 2018-02-23 Roche Glycart Ag Cea protutijela
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
BR112015010993B1 (pt) 2012-11-20 2022-08-30 Sanofi Anticorpos anti-ceacam5, célula hospedeira, imunoconjugado e composição farmacêutica
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CN104948958A (zh) * 2015-07-01 2015-09-30 上海顿格电子贸易有限公司 一种利用热敏电阻限流的led灯
CN108341876B (zh) * 2017-01-22 2021-06-04 中国人民解放军第四军医大学 抗人ceacam5单克隆抗体及其制备方法和应用
AU2019292580A1 (en) * 2018-06-29 2021-02-04 Krystal Biotech, Inc. Compositions and methods for antibody delivery
US20220080053A1 (en) * 2019-02-07 2022-03-17 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
IL302731A (en) * 2020-11-10 2023-07-01 Sanofi Sa Ceacam5 antibody-drug conjugate formulation
JP2024545428A (ja) * 2021-12-02 2024-12-06 サノフイ 癌治療における患者選択のためのｃｅａアッセイ
WO2024108053A1 (en) * 2022-11-17 2024-05-23 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof

Also Published As

Publication number Publication date
DK3199552T3 (da) 2020-03-30
CN104918958B (zh) 2019-12-10
BR112015010993B1 (pt) 2022-08-30
PT3199552T (pt) 2020-03-25
JP6324399B2 (ja) 2018-05-16
CN109180815B (zh) 2022-06-21
HRP20200415T1 (hr) 2020-06-26
EP3199552B1 (en) 2019-12-25
EP3199552A1 (en) 2017-08-02
CA2889962A1 (en) 2014-05-30
US11332542B2 (en) 2022-05-17
EA201590986A1 (ru) 2016-05-31
IL238559A0 (en) 2015-06-30
ECSP15025845A (es) 2016-01-29
KR20200143527A (ko) 2020-12-23
TW201940519A (zh) 2019-10-16
HRP20170743T1 (hr) 2017-07-28
PL3199552T3 (pl) 2020-06-01
KR20150085828A (ko) 2015-07-24
DK2922875T3 (en) 2017-06-06
MA38194A1 (fr) 2018-02-28
WO2014079886A1 (en) 2014-05-30
EP3594243A1 (en) 2020-01-15
KR102408660B1 (ko) 2022-06-15
AU2013349733B2 (en) 2018-08-23
KR20220084193A (ko) 2022-06-21
NZ708528A (en) 2020-07-31
ES2778823T3 (es) 2020-08-12
CY1119219T1 (el) 2018-02-14
MX2015006374A (es) 2015-10-09
HK1215444A1 (en) 2016-08-26
US20180022817A1 (en) 2018-01-25
PT2922875T (pt) 2017-05-31
CR20150258A (es) 2015-06-11
PH12015501092B1 (en) 2019-01-11
LT3199552T (lt) 2020-04-10
EP2922875B1 (en) 2017-03-15
AR093557A1 (es) 2015-06-10
TN2015000177A1 (en) 2016-10-03
ZA201502959B (en) 2016-01-27
KR102194748B1 (ko) 2020-12-23
PE20151180A1 (es) 2015-08-12
UY35147A (es) 2014-06-30
CL2015001321A1 (es) 2015-07-17
EA039377B1 (ru) 2022-01-20
TW201427997A (zh) 2014-07-16
KR20240063172A (ko) 2024-05-09
SI2922875T1 (sl) 2017-06-30
SG11201503285TA (en) 2015-05-28
SI3199552T1 (sl) 2020-06-30
JP2016506370A (ja) 2016-03-03
LT2922875T (lt) 2017-06-12
ES2625742T3 (es) 2017-07-20
HUE033369T2 (en) 2017-11-28
AU2013349733A1 (en) 2015-06-11
MA38194B1 (fr) 2018-12-31
DOP2015000110A (es) 2015-08-16
CA2889962C (en) 2023-10-24
RS55987B1 (sr) 2017-09-29
MY171100A (en) 2019-09-25
US20160108131A1 (en) 2016-04-21
US10457739B2 (en) 2019-10-29
UA120247C2 (uk) 2019-11-11
EP2922875A1 (en) 2015-09-30
AU2018267636A1 (en) 2018-12-13
CN109180815A (zh) 2019-01-11
US9617345B2 (en) 2017-04-11
AU2013349733C1 (en) 2020-10-01
RS60043B1 (sr) 2020-04-30
TWI664192B (zh) 2019-07-01
KR102661801B1 (ko) 2024-04-26
MX358321B (es) 2018-08-14
CA3207769A1 (en) 2014-05-30
CN104918958A (zh) 2015-09-16
IL238559B (en) 2018-10-31
BR112015010993A2 (pl) 2017-08-22
US20220340682A1 (en) 2022-10-27
US20200102401A1 (en) 2020-04-02
PH12015501092A1 (en) 2015-07-27

Similar Documents

Publication Publication Date Title
IL238559A0 (en) Antibodies against ceacam5 and their use
IL254416B (en) Anti-asic1 antibodies and their uses
ZA201500457B (en) Anti-kit antibodies and uses thereof
IL234719A0 (en) Anti-pmel17 antibodies and immunoconjugates
EP2832856A4 (en) ANTI-LAMP5 ANTIBODIES AND USE THEREOF
SG11201407099WA (en) Anti-pcsk9 antibodies and use thereof
EP2879708A4 (en) ANTIBODY AND ANTI-ETBR IMMUNOCONJUGATES
SG11201405881TA (en) Anti-lgr5 antibodies and immunoconjugates
EP2841458A4 (en) MODIFIED ANTIBODY REGIONS AND USES THEREOF
ZA201405554B (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
PL2831117T3 (pl) Przeciwciała anty-TLR4 i ich zastosowania
SG11201504482VA (en) Beta-hexosyl-transferases and uses thereof
EP2879711A4 (en) ANTI-ETBR ANTIBODIES AND IMMUNOCONJUGATES
GB201208372D0 (en) Antibodies and uses thereof